Cognitive impairment associated with schizophrenia (CIAS) refers to reduced cognitive function in schizophrenia patients including impairments in functions such as attention, working memory, verbal fluency, executive function, visual spatial skills, and social cognition. CIAS is one of the core features of schizophrenia and has a significant impact on functional outcomes. Several factors are considered to contribute to CIAS including dysregulated dopamine and/or glutamate neurotransmission, structural brain changes, and genetic factors.
The Global Cognitive Impairment Associated With Schizophrenia (CIAS) Market is estimated to be valued at USD 5.2 Bn in 2024 and is expected to reach USD 7.1 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.1% from 2024 to 2031.
Key players operating in the cognitive impairment associated with schizophrenia are Otsuka Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Alkermes plc., Allergan plc., and Lundbeck A/S.
Increasing research into pharmacological and non-pharmacological interventions for Cognitive Impairment Associated With Schizophrenia (CIAS) Market represents a major opportunity in the market. Companies are exploring improved medications targeting dysregulated neurotransmission as well as digital therapeutics to improve cognitive functions. Geographically, North America dominated the global market in 2021 due to growing awareness regarding CIAS. However, Asia Pacific is expected to witness highest growth over the forecast period owing to rising schizophrenia prevalence and improving access to healthcare in countries like China and India.
Market drivers
Rising prevalence of schizophrenia globally - As per WHO estimates, over 20 million people worldwide suffer from schizophrenia. CIAS affects 70-80% of these patients driving market growth.
Growing awareness regarding impact of CIAS - Improved understanding that CIAS leads to poorer functional outcomes than psychotic symptoms alone is driving demand for treatments targeted at cognitive deficits.
Market restraints
High failure rate of drug development - Numerous CIAS drug development programs have failed during clinical trials posing significant risk to the market.
Lack of approved therapies - Currently there are no Food and Drug Administration approved therapies specifically indicated for treatment of CIAS limiting the market.
Segment Analysis
The global cognitive impairment associated with schizophrenia (CIAS) market can be segmented based on therapeutics, route of administration, pharmacy setting, and geography. Based on therapeutics, the market is segmented into antipsychotics, antidepressants, anxiolytics, mood stabilizers. Antipsychotics serve as the dominating sub-segment as they help manage the positive and negative symptoms such schizophrenia by blocking dopamine and serotonin receptor pathways.
Global Analysis
Regionally, North America holds the largest share in the global CIAS market due to growing awareness and presence of advance healthcare infrastructure in the region. Additionally, Asia Pacific is expected to witness fastest growth in the market owing to improving healthcare facilities and rapid increase in healthcare spending in emerging economies such as China and India. Government initiatives to spread awareness about mental disorders and availability of generic drugs are also contributing to the market growth in Asia Pacific region.
Get this Report in Japanese Language: 統合失調症に伴う認知機能障害（CIAS）市場
Get this Report in Korean Language: 정신분열증과 관련된 인지 장애(CIAS) 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
Some important supplements are essential for the brain to function.
You have to provide your mind with these supplements so that you won't fall prey for cognitive decline as you age.The two best supplements that will keep you going is Vitamin D and Omega-3 fatty acids.
The test has been conducted for more than 4,500 people, and it has been proven that people with very low Vitamin D level are suffering from cognitive impairment.Depression is another decisive mental health battle that most of the people are fighting with these days irrespective of their age.
The increase of Vitamin D in blood level will surely create an impact on the depression too.
Research has proven that for every ten units of more Vitamin D in the blood, there is eight percent less chance of getting depression.Vitamin D plays a very crucial role when it comes to the improvement of brain health.
It is essential for you to provide your body with enough Vitamin D supplement so that your brain works more actively and do not get depressed at times.Omega-3 Fatty AcidsMost of the people do not get enough Omega-3 from their diet but this Omega-3 impacts the brain health a lot.
